Corvus Pharmaceuticals Inc. (CRVS) shares shot up 115% on Tuesday after the clinical-stage biopharma company said that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19.The stock surged to $5.85 in early morning trading. Novavax reported that the first cohort of 5 patients enrolled in the study was treated at Temple University Hospital in Philadelphia. The initiation follows the U.S. Food and Drug Administration’s (FDA) review and approval of the company’s investigational new drug (IND) application for the COVID-19 study. The trial will evaluate anti-viral antibody response in up to 30 COVID-19 …read more
Source:: Yahoo Finance